Proactive Investors - Run By Investors For Investors

Pfizer, Amgen , Clovis Oncology and more - PRE-MARKET

A look at what stocks are moving the needle, up and down, before the bell in New York
Pfizer, Amgen , Clovis Oncology and more - PRE-MARKET
Biotech stocks are in focus in pre-market in New York

It should be rather more of a busy day on Wall Street today after thin volumes on Monday due to the Columbus Day holiday.

Stocks to watch on the day include Pfizer (NYSE:PFE), which jumped up  1.13% to US$36.55 after hours.

It has emerged that the group is potentially considering the sale of its consumer health unit.

The business posted US$3.4bn in revenue last year, which was "distinct enough" from the core business that there could potential for it to be more valuable outside the company.

Well-known brands at the business include ChapStick.

Elsewhere, the biopharma firm Amgen Inc (NASDAQ:AMGN)  saw shares nudge 0.11% lower after hours to US$ 185.25  after the group said the key FDA  had accepted what's called a supplemental biologics license application for Prolia.

The drug is an antibody  to treat osteoporosis, treatment-induced bone loss, and giant cell tumor of bone, among others.

Elsewhere, Clovis Oncology Inc (NASDAQ:CLVS) saw shares add 1.80% to US$83.50 after the bell, after it revealed that it had submitted a supplemental new drug application to the FDA for anti cancer agent rucaparib.

Also in pre-market, Imperva Inc (NASDAQ:IMPV)  shares lost 2.53% on the day yesterday, and lost 1.69% after the bell to US$44.25 after it reported the resignation of its finance chief Terry Schmid.

Schmid named Aaron Kuan as the new person in the role on an interim basis effective November 16, 2017.

View full PFE profile View Profile

Pfizer Timeline

November 23 2015

Related Articles

August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use